CTOs on the Move

Pharmaceutical Product Development

www.ppd.com

 
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.ppd.com
  • 929 N Front St
    Wilmington, NC USA 28401
  • Phone: 910.251.0081

Executives

Name Title Contact Details
Patricia Christiansen
 Sr. Director of Consumer Marketing Technology Infrastructure Profile

Similar Companies

Egenomics

Egenomics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quintiles

Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Waste Reduction

Waste Reduction is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Linnaeus Therapeutics

Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.

Q32 Bio

Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.